These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22584716)

  • 1. Temozolomide in aggressive pituitary adenomas and carcinomas.
    Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of pituitary neoplasms with temozolomide: a review.
    Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
    Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
    Lau Q; Scheithauer B; Kovacs K; Horvath E; Syro LV; Lloyd R
    Pituitary; 2010 Dec; 13(4):367-79. PubMed ID: 20740317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
    Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
    Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
    Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
    Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of temozolomide in the treatment of aggressive pituitary tumors.
    Liu JK; Patel J; Eloy JA
    J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
    Salehi F; Scheithauer BW; Kros JM; Lau Q; Fealey M; Erickson D; Kovacs K; Horvath E; Lloyd RV
    J Neurooncol; 2011 Sep; 104(3):647-57. PubMed ID: 21311951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
    Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
    Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
    Widhalm G; Wolfsberger S; Preusser M; Woehrer A; Kotter MR; Czech T; Marosi C; Knosp E
    Cancer; 2009 Mar; 115(5):1070-80. PubMed ID: 19156926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
    Chen C; Yin S; Zhang S; Wang M; Hu Y; Zhou P; Jiang S
    Medicine (Baltimore); 2017 Nov; 96(47):e8733. PubMed ID: 29381964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
    Raverot G; Castinetti F; Jouanneau E; Morange I; Figarella-Branger D; Dufour H; Trouillas J; Brue T
    Clin Endocrinol (Oxf); 2012 Jun; 76(6):769-75. PubMed ID: 22404748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
    Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
    McCormack AI; Wass JA; Grossman AB
    Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
    Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
    J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
    J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
    Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
    Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.
    Lasolle H; Raverot G
    Presse Med; 2016 Jun; 45(6 Pt 2):e211-6. PubMed ID: 27242211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
    Zuhur SS; Tanik C; Karaman Ö; Velet S; Çil E; Öztürk FY; Özkayalar H; Müslüman AM; Altuntaş Y
    Endocrine; 2011 Oct; 40(2):222-7. PubMed ID: 21792693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.